References
- Draycott T, Lewis G, Stephens I. Executive summary. Centre for Maternal and Child Enquiries (CMACE). BJOG 2011;118:e12–e21
- Ismail G. Hypertensive disease in pregnancy. In: Mukuden K, Kosky R, eds. Report on the confidential enquiries into maternal deaths in Malaysia 2006–2008. Kuala Lumpur, Malaysia: Ministry of Health Government Press; 2011:35–41
- Goldman-Wohl D, Yagel S. NK cells and pre-eclampsia. Repro Biomed Online 2008;16:227–31
- Lydakis C, Beevers DG, Beevers M, Lip GY. Obstetric and neonatal outcome following chronic hypertension in pregnancy among different ethnic groups. QJM 1998;91:837–44
- Lydakis C, Beevers M, Beevers DG, Lip GY. The prevalence of pre-eclampsia and obstetric outcome in pregnancies of normotensive and hypertensive women attending a hospital specialist clinic. Int J Clin Pract 2001;55:361–7
- Pijnenborg R, Vercruysse L, Hanssens M. The uterine spiral arteries in human pregnancy: facts and controversies. Placenta 2006;27:939–58
- Huppertz B. Placental origins of pre-eclampsia: challenging the current hypothesis. Hypertension 2008;51:970–5
- Zhou Y, Damsky CH, Fisher SJ. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesions phenotype. One cause of defective endovascular invasion in this syndrome? J Clin Invest 1997;99:2152–64
- Roberts JM, Redman CW. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet 1993;341:1447–51
- Meekins JW, Pijnenborg R, Hanssens M, et al. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol 1994;101:669–74
- Repke JT, Robinson JN. The prevention and management of pre-eclampsia and eclampsia. Int J Gynaecol Obstet 1998;62:1–9
- Orange SJ, Painter D, Horvath J, et al. Placental endothelial nitric oxide synthase localization and expression in normal human pregnancy and pre-eclampsia. Clin Exp Pharmacol Physiol 2003;30:376–81
- Patki A, Pawar VC. Modulating fertility outcome in assisted reproductive technologies by the use of dydrogesterone. Gynecol Endocrinol 2007;23:68–72
- Daya S. Luteal support: progestogens for pregnancy protection. Maturitas 2009;65:S29–34
- Omar MH, Mashita MK, Lim PS, Jamil MA. Dydrogesterone in threatened abortion: pregnancy outcome. J Steroid Biochem Mol Biol 2005;97:421–5
- Colombo D, Ferraboschi P, Prestileo P, Toma L. A comparative molecular modeling study of dydrogesterone with other progestational agents through theoretical calculations and nuclear magnetic resonance spectroscopy. J Steroid Biochem Mol Biol 2006;98:56–62
- Schindler AE. Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium. Maturitas 2009;65:S3–11
- Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet 2001;357:53–6
- Waught JS, Smith MC. Hypertensive disorders. In: Edmonds DK, ed. Dewhurst textbook of obstetrics & gynaecology. 8th ed. West Sussex, England: John Wiley & Sons Ltd; 2012:101–10
- ACOG Committee Opinion. No 348. American College of Obstetricians and Gynecologists. Obstet Gynecol 2006;108:1319–22
- Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 2003;102:181–92
- Rylance PB, Brincat M, Lafferty K, et al. Natural progesterone and antihypertensive action. Br Med J 1985;290:13–14
- Kristiansson P, Wang JX. Reproductive hormones and blood pressure during pregnancy. Hum Reprod 2001;16:13–17
- Sammour MB, el-Kabarity H, Fawzy MM, Schindler AE. Prevention and treatment of pregnancy-induced hypertension (preeclampsia) with progestogens. J Steroid Biochem Mol Biol 2005;97:439–40
- Karumanchi SA, Lim KH, August P. Pathogenesis of preeclampsia. www.Uptodate.com 2011:1–14
- Brosens I, Pijnenborg R, Vercruysse L, Romero R. The “Great Obstetrical Syndroms” are associated with disorders of deep placentation. Am J Obstet Gynecol 2011;204:193–8
- Schindler AE. Immunology and progestins in pregnancy. Gynecol Endocrinol 1999;13:47–50
- Schindler AE. Endocrinology of pregnancy: consequences for the diagnosis and treatment of pregnancy disorders. J Steroid Biochem Mol Biol 2005;97:386–8
- Wardell SE, Edwards DP. Mechanisms controlling agonist and antagonist potential of selective progesterone receptor modulators (SPRMs). Semin Reprod Med 2005;23:9–21
- Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systemic review of controlled studies. BMJ 2005;330:565–67
- Bachetti T, Comini L, Curello S, et al. Co-expression and modulation of neuronal and endothelial nitric oxide synthase in human endothelial cells. J Mol Cell Cardiol 2004;37:939–45
- Bardeguez AD, McNerney R, Frieri M, et al. Cellular immunity in preeclampsia: alterations in T-lymphocyte subpopulations during early pregnancy. Obstet gynecol 1991;77:859–62
- Li TC, MacLeod I, Singhal V, Duncan SL. The obstetric and neonatal outcome of pregnancy in women with a previous history of infertility: a prospective study. Br J Obstet Gynaecol 1991;98:1087–92
- Venn A, Lumley J. Births after a period of infertility in Victorian women 1982–1990. Aust N Z J Obstet Gynaecol 1993;33:379–84
- Reubinoff BE, Samueloff A, Ben-Haim M, et al. Is the obstetric outcome of in vitro fertilized singleton gestations different from natural ones? A controlled study. Fertil Steril 1997;67:1077–83
- Caughey AB, Musci TJ. Complications of term pregnancies beyond 37 weeks of gestation. Obstet Gynecol 2004;103:57–62
- Heimstad R, Romundstad PR, Eik-Nes SH, Salvesen KA. Outcomes of pregnancy beyond 37 weeks gestation. Obstet Gynecol 2006;108:500–8
- Simoncini T, Caruso A, Giretti MS, et al. Effects of dydrogesterone and of its stable metabolite, 20-alpha-dihydrodydrogesterone, on nitric oxide synthesis in human endothelial cells. Fertil Steril 2006;86:1235–42